Speaker: Professor John Spertus, University of Missouri-Kansas City and Saint Luke’s Mid America Heart Institute, Kansas City, USA
Title: The ISCHEMIA Trial – Identifying the Optimal Management Strategy for patients with Stable Ischemic Heart Disease
Chair: Dr Rosanna Tavella, Clinical Data Manager, Translational Vascular Function Research Collaborative, The University of Adelaide and Basil Hetzel Institute, TQEH
Speaker biography: Prof John Spertus is a cardiologist and the Lauer/Missouri Endowed Chair and Professor of Medicine at the University of Missouri-Kansas City, where he serves as Clinical Director of Outcomes Research at Saint Luke’s Mid America Heart Institute. He is an internationally-recognised leader in Cardiovascular Outcomes Research, having pioneered the measurement of patients’ health status in cardiovascular disease, founded the American Heart Association Scientific Forum on Quality of Care and Outcomes Research, served as Chair of the American Heart Association QCOR Council and having written >800 peer-reviewed manuscripts. His achievements are numerous and include listing in the Thomson Reuters Hi-cite as ‘One of the Most Influential Scientific Minds in the World’ and the 2018 American Heart Association Distinguished Scientist Award. He founded the Cardiovascular Outcomes Research Consortium and CV Outcomes, a non-profit organisation dedicated to advancing health care quality and outcomes research in cardiovascular disease and Health Outcomes Sciences, a biotechnology start-up which has transformed statistical risk models into automated evidence-based decision support solutions. Prof John Spertus is an Adjunct Professor at The University of Adelaide where he brings his innovative and impactful science to define and shape evidence-based, personalised medicine in Australia.
Lunch will be provided following the seminar.